ASCO 2017 - Metastatic castration-resistant prostate cancer: indoximod after sipuleucel-T boosts PFSl in phase 2 trial

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • The maximum tolerated dose of indoximod (NewLink Genetics) 2400 mg/d twice daily for 24 wk, after standard treatment with sipuleucel-T (Provenge, Dendreon), was well tolerated and led to significant improvements in radiographic PFS.

Why this matters

  • Prostate cancer standard...